Central Nervous System Embryonal Carcinoma
Associated Genetic Biomarkers
NCI Definition: A malignant germ cell tumor of the central nervous system composed of large cells that proliferate in cohesive nests and sheets. In rare occasions, tumor cells may replicate the structure of the early embryo, forming "embryoid bodies" replete with germ discs and miniature amniotic cavities. Additional morphologic characteristics include enlarged nucleoli, abundant clear to somewhat violet-hued cytoplasm, a high mitotic rate and zones of coagulative necrosis. (Adapted from WHO) 
Central nervous system embryonal carcinomas most frequently harbor alterations in CDKN1B, RAD52, PIK3C2G, MCL1, and KRAS .
CDKN1B Amplification, RAD52 Amplification, PIK3C2G Amplification, MCL1 Amplification, and KRAS Amplification are the most common alterations in central nervous system embryonal carcinoma .
There is 1 clinical trial for central nervous system embryonal carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains central nervous system embryonal carcinoma as an inclusion criterion, 1 is phase 1 (1 open).
Therapeutic autologous lymphocytes is the most common intervention in central nervous system embryonal carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.